Has Valeria Cohran received payments from drug or device companies?

Yes. Drug and device makers reported $211,981 in general payments to Valeria Cohran across 241 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Valeria Cohran did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Valeria Cohran come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Valeria Cohran

Pediatric Gastroenterology · Chicago, ILNPI 1972611234

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $158,772 of the $211,981 with a category attached, or 74.9%. 7 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 54.1% of the total. 2025 is the largest year on record at $75,729, 6.8 times the $11,100 reported in 2019. Among pediatric gastroenterology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$211,981in general payments, 2019–2025

Across 241 payments — averaging $879.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Takeda Pharmaceuticals U.S.A., Inc.$115K
Alcresta Therapeutics, Inc.$85K
Shire North American Group Inc$9K
Baxter Healthcare$3K
Eli Lilly$625
Incyte Corporation$129
plus $101 from 1 others

$53,088in research payments, 2019–2025

Across 14 payments — averaging $3792.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Shire North American Group Inc$46K
Takeda Pharmaceuticals U.S.A., Inc.$8K

What the payments were for

Consulting fees$21,19510%
Speaking & faculty fees$158,77275%
Travel & lodging$24,52412%
Food & beverage$4,4912%
Education$3,0001%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	126	$114,727
Alcresta Therapeutics, Inc.	99	$84,853
Shire North American Group Inc	9	$8,531
Baxter Healthcare	2	$3,015
Eli Lilly	1	$625
Incyte Corporation	1	$129
Fresenius Kabi USA, LLC	3	$101

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$211,981 in reported general payments places this provider in the 95th percentile of 58 pediatric gastroenterology providers in Illinois.

See all pediatric gastroenterology providers in Illinois →

Other pediatric gastroenterology in Chicago

Joshua WechslerChicago$433K
Lee BassChicago$149K
Alyssa KriegermeierChicago$22K
Ritu VermaChicago$8K
Stefano GuandaliniChicago$7K
Ranjana GokhaleChicago$4K
Tiffany PattonChicago$3K
Jeffrey BrownChicago$3K
Barry WershilChicago$3K
Estella AlonsoChicago$2K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →